LipoScience, Inc. is a vitro diagnostic company. The Company's diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:LPDX
- CUSIP: 53630M10
- Web: N/A
- Trailing P/E Ratio:
- Foreward P/E Ratio: -6.24
- P/E Growth:
Frequently Asked Questions for LipoScience (NASDAQ:LPDX)
What is LipoScience's stock symbol?
LipoScience trades on the NASDAQ under the ticker symbol "LPDX."
How were LipoScience's earnings last quarter?
LipoScience Inc (NASDAQ:LPDX) released its earnings results on Wednesday, November, 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The company had revenue of $8.56 million for the quarter, compared to analysts' expectations of $8.80 million. During the same period last year, the firm posted ($0.31) EPS. View LipoScience's Earnings History.
Who are some of LipoScience's key competitors?
Some companies that are related to LipoScience include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy LipoScience stock?
Shares of LipoScience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of LipoScience stock cost?
One share of LipoScience stock can currently be purchased for approximately $5.24.
Consensus Ratings for LipoScience (NASDAQ:LPDX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for LipoScience (NASDAQ:LPDX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for LipoScience (NASDAQ:LPDX)Earnings History by Quarter for LipoScience (NASDAQ:LPDX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/12/2014||Q3 14||($0.26)||($0.28)||$8.80 million||$8.56 million||View||N/A|
|8/12/2014||Q2 2014||($0.24)||($0.27)||$8.90 million||$9.05 million||View||N/A|
|5/12/2014||Q1 14||($0.19)||($0.13)||$12.25 million||$12.01 million||View||N/A|
|3/10/2014||Q413||($0.24)||($0.17)||$12.71 million||$12.72 million||View||N/A|
Earnings Estimates for LipoScience (NASDAQ:LPDX)
Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.84 EPS
Dividend History for LipoScience (NASDAQ:LPDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for LipoScience (NASDAQ:LPDX)Insider Trades by Quarter for LipoScience (NASDAQ:LPDX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/4/2013||Daniel Levangie||Director||Buy||10,000||$4.17||$41,700.00|| |
|12/4/2013||E. Duffy Mcdonald||VP||Sell||12,731||$4.07||$51,815.17|| |
|11/25/2013||James Hurley||Director||Buy||5,100||$3.91||$19,941.00|| |
|11/18/2013||Robert Greczyn, Jr.||CEO||Buy||10,000||$4.15||$41,500.00|| |
|1/30/2013||Buzz Benson||Director||Buy||50,000||$9.00||$450,000.00|| |
|1/30/2013||Three Arch Capital Lp||Major Shareholder||Buy||215,000||$9.00||$1,935,000.00|| |
Headline Trends for LipoScience (NASDAQ:LPDX)
Latest Headlines for LipoScience (NASDAQ:LPDX)
LipoScience (LPDX) Chart for Wednesday, May, 24, 2017